A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma
Phase 1
20 Years
75 Years
20 Years
75 Years
Not Enrolling
Both
Lymphoma
Both
Lymphoma
Trial Information
A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma
Inclusion Criteria:
- Patients who relapsed after complete or partial response, or ineffective in previous
chemotherapy
Exclusion Criteria:
- Patients with history of chemotherapy, antibody therapy, radiotherapy, during the
previous 4 weeks (6 months for radioisotope-labeled antibody)
- Any uncontrolled concomitant illness
- Are pregnant or breast-feeding
- Serious drug or food allergy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety
Outcome Time Frame:
Duration of Trial
Safety Issue:
No
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Merck
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
MK-0683-030
NCT ID:
NCT00127140
Start Date:
June 2005
Completion Date:
April 2012
Related Keywords:
- Lymphoma
- Lymphoma
Name | Location |
|---|
